Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Maxim cuts Aridis Pharma to hold

Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...

August 16, 2022

Markets

Dawson James cuts Aditxt Therapeutics PT to $1 from $6

Dawson James Securities slashed its price target for Aditxt Therapeutics (NASDAQ:ADTX) to $1 from $6, but maintained a “buy” rating, noting that cash is tight and a capital raise is expected. The stock closed at 17...

August 16, 2022

Markets

Stifel cuts IDEAYA to hold on skepticism of MAT2A cancer program

Stifel downgraded IDEAYA Biosciences (NASDAQ:IDYA) to “hold” from “buy” and reduced its price target to $13 from $16 “on the belief that it’s difficult to gain high conviction in the MTAP/MAT2A thesis (we ascribe...

August 15, 2022

Markets

Cantor starts Mereo BioPharma at OW; PT $4

Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...

August 12, 2022

Markets

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...

August 12, 2022

Markets

Cantor cuts TerrAscend to neutral on model update post Q2 miss

Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...

August 12, 2022

Markets

SVB cuts 4D Molecular to MP on elevated risk to Fabry program

SVB Securities downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) to “market perform” from “outperform” and reduced its price target to $12, citing an elevated risk to the lead Fabry disease program, along with an...

August 12, 2022

Markets

BTIG ups Acutus PT to $2.50 on Q2, strategy shift plan results

BTIG raised its price target for Acutus Medical (NASDAQ:AFIB) to $2.50 from $1.50 after the company beat consensus estimates for second quarter revenue. The stock closed at $1.66 on Aug. 11. Acutus Medical is a cardiac...

August 12, 2022

Markets

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

August 10, 2022

Markets

Dawson James cuts Mesoblast to neutral on potential capital raise

Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...

August 8, 2022

Markets

Cantor cuts Galmed to neutral on limited insights into programs

Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...

August 4, 2022

Markets

Research Capital ups Valeo Pharma PT on new drug licensing

Research Capital raised its price target for Valeo Pharma (CSE:VPH) to $1 (Canadian) from 70 cents and maintained a “speculative buy” rating after the company closed a $40-million (U.S.) non-dilutive financing from...

August 2, 2022

Markets

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

August 2, 2022

Markets

Cantor starts Clever Leaves at OW; PT $4.50

Cantor Fitzgerald initiated coverage of Clever Leaves Holdings (NASDAQ:CLVR) with an “overweight” rating and $4.50 price target. The stock closed at 92 cents on July 27. “In relative terms, the stock offers better ‘pure...

August 1, 2022

Markets

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix Pharmaceuticals (NASDAQ:TNXP) is collaborating with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop Tonix’s TNX-801 as a vaccine...

July 28, 2022

Markets

Cantor downgrades ObsEva on restructuring and likely CRL

Cantor Fitzgerald downgraded ObsEva (NASDAQ:OBSV) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company announced a corporate restructuring and refocus of its development and...

July 28, 2022

Markets

BTIG starts Keros at buy; PT $80

BTIG launched coverage of Keros Therapeutics (NASDAQ:KROS) with a “buy” rating and $80 price target. The stock closed at $28.53 on July 25. Analyst Julian Harrison writes that following Acceleron’s impressive foray into...

July 26, 2022

Markets

Maxim upgrades Agile on financing and contraceptive tailwind

Maxim Group upgraded Agile Therapeutics (NASDAQ:AGRX) to “buy” from “hold” and set a $1 price target, after the company closed a recent equity offering, enacted austerity measures and refined its commercial efforts. The...

July 26, 2022

Markets

Ladenburg starts Liquidia at buy; PT $15

Ladenburg Thalmann initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $15 price target. The stock closed at $5.03 on July 21. Liquidia is a commercial-stage biotechnology company currently focused on...

July 22, 2022

Markets

Cantor starts BioVie at OW; PT $7

Cantor Fitzgerald launched coverage of BioVie (NASDAQ:BIVI) with an “overweight” rating and $7 price target. The stock closed at $2.10 on July 21. BioVie is developing NE3107, an orally bioavailable anti-inflammatory...

July 22, 2022

Markets

Dawson James downgrades ProPhase Labs to sell on licensing deal

Dawson James downgraded ProPhase Labs (NASDAQ:PRPH) to “sell” from “neutral” with a price target of $5 after the company announced a license agreement with Global BioLife. Shares of ProPhase were quoted at $11.71, down...

July 21, 2022

Markets

SVB starts Pliant Therapeutics at OW: PT $33

SVB Securities initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “outperform” rating and price target of $33. The stock closed at $19.22 on July 19. Pliant is a clinical-stage biopharmaceutical company...

July 20, 2022

Maxim cuts Aridis Pharma to hold

Dawson James cuts Aditxt Therapeutics PT to $1 from $6

Stifel cuts IDEAYA to hold on skepticism of MAT2A cancer program

Cantor starts Mereo BioPharma at OW; PT $4

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

Cantor cuts TerrAscend to neutral on model update post Q2 miss

SVB cuts 4D Molecular to MP on elevated risk to Fabry program

BTIG ups Acutus PT to $2.50 on Q2, strategy shift plan results

Cantor starts MindMed at OW; PT $3

Dawson James cuts Mesoblast to neutral on potential capital raise

Cantor cuts Galmed to neutral on limited insights into programs

Research Capital ups Valeo Pharma PT on new drug licensing

Maxim starts scPharmaceuticals at buy; PT $10

Cantor starts Clever Leaves at OW; PT $4.50

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Cantor downgrades ObsEva on restructuring and likely CRL

BTIG starts Keros at buy; PT $80

Maxim upgrades Agile on financing and contraceptive tailwind

Ladenburg starts Liquidia at buy; PT $15

Cantor starts BioVie at OW; PT $7

Dawson James downgrades ProPhase Labs to sell on licensing deal

SVB starts Pliant Therapeutics at OW: PT $33

General

More